Use of Fabry disease treatment leads to ‘robust’ cuts in clinical trial
The main part of a Phase 2 trial testing Acelink Therapeutics‘ AL01211 in men with Fabry disease is now complete, and its developer is reporting that the oral treatment candidate showed a favorable safety profile and led to “robust” reductions in disease biomarkers. Given these positive data, Acelink said…